31536 Federal Register / Vol. 86, No. 112 / Monday, June 14, 2021 / Notices 

requirement to persons with whom the 

lessee does business relating to this 

lease by including this term as a 

condition in their contracts and other 

transactions. 

XVII. Final Sale Notice 

The development of the FSN will be 

informed the EA, related consultations 

and comments received during the PSN 

comment period. The FSN will provide 

the final details concerning the offering 

and issuance of OCS commercial wind 

energy leases in the New York Bight. 

The FSN will be published in the 

Federal Register at least 30 days before 

the lease sale is conducted and will 

provide the date and time of the 

auction. 

XVIII. Changes to Auction Details 

The Program Manager of BOEM’s 

Office of Renewable Energy Programs 

has the discretion to change any auction 

detail specified in the FSN, including 

the date and time, if the Program 

Manager deems that events outside 

BOEM’s control may interfere with a fair 

and proper lease sale process. Such 

events may include, but are not limited 

to: Natural disasters (e.g., earthquakes, 

hurricanes, floods, and blizzards), wars, 

riots, act of terrorism, fire, strikes, civil 

disorder, Federal Government 

shutdowns, cyberattacks against 

relevant information systems, or other 

events of a similar nature. In case of 

such events, BOEM will notify all 

qualified bidders via email, phone, and 

BOEM’s website at: https://

www.boem.gov/NY-Bight/. Bidders 

should call 703–787–1121 if they have 

concerns. 

XIX. Appeals 

The appeals and reconsideration 

procedures are provided in BOEM’s 

regulations at 30 CFR 585.225 and 

585.118(c). Pursuant to 30 CFR 585.225: 

(a) If BOEM rejects your bid, BOEM 

will provide a written statement of the 

reasons and refund any money 

deposited with your bid, without 

interest. 

(b) You will then be able to ask the 

BOEM Director for reconsideration, in 

writing, within 15-business days of bid 

rejection under 30 CFR 585.118(c)(1). 

The Director will send you a written 

response either affirming or reversing 

the rejection. 

The procedures for appealing final 

decisions with respect to lease sales are 

described in 30 CFR 585.118(c). 

XX. Public Participation 

BOEM does not consider anonymous 

comments: Please include your name 

and address as part of your submittal. 

You should be aware that your entire 

comment, including your name, 

address, and any other personal 

identifying information (PII) included in 

your comment, may be made publicly 

available. All submissions from 

identified individuals, businesses, and 

organizations will be available for 

public viewing on regulations.gov. 

In order for BOEM to withhold from 

disclosure your PII, you must identify 

any information contained in the 

submittal of your comments that, if 

released, would constitute a clearly 

unwarranted invasion of your personal 

privacy. You must also briefly describe 

any possible harmful consequence(s) of 

the disclosure of information, such as 

embarrassment, injury or other harm. 

BOEM is unable to guarantee that your 

PII will be protected from public 

disclosure because a court may 

determine that the benefits of disclosure 

about who may influence public policy 

outweigh possible harms. 

XXI. Protection of Privileged or 

Confidential Information 

BOEM will protect privileged or 

confidential information that you 

submit, as required by the Freedom of 

Information Act (FOIA) and 30 CFR 

585.113. Exemption 4 of FOIA applies 

to ‘‘trade secrets and commercial or 

financial information that you submit 

that is privileged or confidential.’’ 5 

U.S.C. 552(b)(4). If you wish to protect 

the confidentiality of such information, 

clearly mark it ‘‘Contains Privileged or 

Confidential Information’’ and consider 

submitting such information as a 

separate attachment. BOEM will not 

disclose such information, except as 

required by FOIA. Information that is 

not labeled as privileged or confidential 

may be regarded by BOEM as suitable 

for public release. Further, BOEM will 

not treat as confidential aggregate 

summaries of otherwise nonconfidential information. 

a. Access to Information (54 U.S.C. 

307103): BOEM is required, after 

consultation with the Secretary of the 

Interior, to withhold the location, 

character, or ownership of historic 

resources if it determines that disclosure 

may, among other things, cause a 

significant invasion of privacy, risk 

harm to the historic resources or impede 

the use of a traditional religious site by 

practitioners. Tribal entities and other 

interested parties should designate 

information that they wish to be held as 

confidential and provide the reasons 

why BOEM should do so. 

Authority: This PSN is published pursuant 

to section 8(p) of the OCS Lands Act (43 

U.S.C. 1337(p)) and the implementing 

regulations at 30 CFR part 585, including 

sections 585.211 and 585.216. 

Amanda Lefton, 

Director, Bureau of Ocean Energy 

Management. 

[FR Doc. 2021–12442 Filed 6–11–21; 8:45 am] 

BILLING CODE 4310–MR–P 

INTERNATIONAL TRADE 

COMMISSION 

[Investigation No. 337–TA–1167] 

Notice of Request for Submissions on 

the Public Interest; Certain 

Laparoscopic Surgical Staplers, 

Reload Cartridges, and Components 

Thereof 

AGENCY: U.S. International Trade 

Commission. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that on 

June 8, 2021, the presiding 

administrative law judge (‘‘ALJ’’) issued 

an Initial Determination on Violation of 

Section 337. The ALJ also issued a 

Recommended Determination on 

remedy and bonding should a violation 

be found in the above-captioned 

investigation. The Commission is 

soliciting submissions on public interest 

issues raised by the recommended relief 

should the Commission find a violation. 

This notice is soliciting comments from 

the public only. 

FOR FURTHER INFORMATION CONTACT: 

Benjamin S. Richards, Office of the 

General Counsel, U.S. International 

Trade Commission, 500 E Street SW, 

Washington, DC 20436, telephone (202) 

708–5453. Copies of non-confidential 

documents filed in connection with this 

investigation may be viewed on the 

Commission’s electronic docket (EDIS) 

at https://edis.usitc.gov. For help 

accessing EDIS, please email 

EDIS3Help@usitc.gov. General 

information concerning the Commission 

may also be obtained by accessing its 

internet server at https://www.usitc.gov. 

Hearing-impaired persons are advised 

that information on this matter can be 

obtained by contacting the 

Commission’s TDD terminal on (202) 

205–1810. 

SUPPLEMENTARY INFORMATION: Section 

337 of the Tariff Act of 1930 provides 

that, if the Commission finds a 

violation, it shall exclude the articles 

concerned from the United States: 

unless, after considering the effect of such 

exclusion upon the public health and 

welfare, competitive conditions in the United 

States economy, the production of like or 

directly competitive articles in the United 

States, and United States consumers, it finds 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 86, No. 112 / Monday, June 14, 2021 / Notices 31537 

that such articles should not be excluded 

from entry. 

19 U.S.C. 1337(d)(1). A similar 

provision applies to cease and desist 

orders. 19 U.S.C. 1337(f)(1). 

The Commission is soliciting 

submissions on public interest issues 

raised by the recommended relief 

should the Commission find a violation, 

specifically: A limited exclusion order 

directed to certain laparoscopic surgical 

staplers, reload cartridges, and 

components thereof imported, sold for 

importation, and/or sold after 

importation by respondents Intuitive 

Surgical Inc.; Intuitive Surgical 

Operations, Inc.; Intuitive Surgical 

Holdings, LLC; and Intuitive Surgical S. 

De R.L. De C.V.; and cease and desist 

orders directed to the same. Parties are 

to file public interest submissions 

pursuant to 19 CFR 210.50(a)(4). 

The Commission is interested in 

further development of the record on 

the public interest in this investigation. 

Accordingly, members of the public are 

invited to file submissions of no more 

than five (5) pages, inclusive of 

attachments, concerning the public 

interest in light of the ALJ’s 

Recommended Determination on 

Remedy and Bonding issued in this 

investigation on June 8, 2021. 

Comments should address whether 

issuance of the recommended remedial 

orders in this investigation, should the 

Commission find a violation, would 

affect the public health and welfare in 

the United States, competitive 

conditions in the United States 

economy, the production of like or 

directly competitive articles in the 

United States, or United States 

consumers. 

In particular, the Commission is 

interested in comments that: 

(i) Explain how the articles 

potentially subject to the recommended 

remedial orders are used in the United 

States; 

(ii) identify any public health, safety, 

or welfare concerns in the United States 

relating to the recommended orders; 

(iii) identify like or directly 

competitive articles that complainant, 

its licensees, or third parties make in the 

United States which could replace the 

subject articles if they were to be 

excluded; 

(iv) indicate whether complainant, 

complainant’s licensees, and/or thirdparty suppliers have the capacity to 

replace the volume of articles 

potentially subject to the recommended 

orders within a commercially 

reasonable time; and 

(v) explain how the recommended 

orders would impact consumers in the 

United States. 

Written submissions must be filed no 

later than by close of business on July 

8, 2021. 

Persons filing written submissions 

must file the original document 

electronically on or before the deadlines 

stated above. The Commission’s paper 

filing requirements in 19 CFR 210.4(f) 

are currently waived. 85 FR 15798 

(March 19, 2020). Submissions should 

refer to the investigation number (‘‘Inv. 

No. 337–TA–1167’’) in a prominent 

place on the cover page and/or the first 

page. See Handbook for Electronic 

Filing Procedures, https://

www.usitc.gov/documents/handbook_

on_filing_procedures.pdf.) Persons with 

questions regarding filing should 

contact the Secretary (202–205–2000). 

Any person desiring to submit a 

document to the Commission in 

confidence must request confidential 

treatment. All such requests should be 

directed to the Secretary to the 

Commission and must include a full 

statement of the reasons why the 

Commission should grant such 

treatment. See 19 CFR 201.6. Documents 

for which confidential treatment by the 

Commission is properly sought will be 

treated accordingly. All information, 

including confidential business 

information and documents for which 

confidential treatment is properly 

sought, submitted to the Commission for 

purposes of this Investigation may be 

disclosed to and used: (i) By the 

Commission, its employees and Offices, 

and contract personnel (a) for 

developing or maintaining the records 

of this or a related proceeding, or (b) in 

internal investigations, audits, reviews, 

and evaluations relating to the 

programs, personnel, and operations of 

the Commission including under 5 

U.S.C. Appendix 3; or (ii) by U.S. 

government employees and contract 

personnel, solely for cybersecurity 

purposes. All contract personnel will 

sign appropriate nondisclosure 

agreements. All nonconfidential written 

submissions will be available for public 

inspection on EDIS. 

This action is taken under the 

authority of section 337 of the Tariff Act 

of 1930, as amended (19 U.S.C. 1337), 

and in Part 210 of the Commission’s 

Rules of Practice and Procedure (19 CFR 

part 210). 

By order of the Commission. 

Issued: June 9, 2021. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2021–12409 Filed 6–11–21; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–850] 

Importer of Controlled Substances 

Application: Usona Institute 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Usona Institute has applied to 

be registered as an importer of basic 

class(es) of controlled substance(s). 

Refer to Supplemental Information 

listed below for further drug 

information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before July 14, 2021. Such persons 

may also file a written request for a 

hearing on the application on or before 

July 14, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing must 

be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for a 

hearing should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/OALJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DPW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on May 10, 2021, Usona 

Institute, 2780 Woods Hollow Road, 

Room 2412, Fitchburg, Wisconsin 

53711–5370, applied to be registered as 

an importer of the following basic 

class(es) of controlled substance(s): 

Controlled substance Drug 

code Schedule 

5-Methoxy-N-Ndimethyltryptamine.7431 I 

Dimethyltryptamine ... 7435 I 

Psilocybin ................. 7437 I 

Psilocyn .................... 7438 I 

The institute plans to import the 

listed controlled substances to be used 

for research and analytical purposes. 

The materials will not be used for 

clinical trials or bulk manufacture. No 


lotter on DSK11XQN23PROD with NOTICES1